Literature DB >> 17239451

Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.

Jenelle L Dorner1, Benjamin R Miller, Scott J Barton, Tyler J Brock, George V Rebec.   

Abstract

Ethological assessment of murine models of Huntington's disease (HD), an inherited neurodegenerative disorder, enables correlation between phenotype and pathophysiology. Currently, the most characterized model is the R6/2 line that develops a progressive behavioral and neurological phenotype by 6 weeks of age. A recently developed knock-in model with 140 CAG repeats (KI) exhibits a subtle phenotype with a longer progressive course, more typical of adult-onset HD in humans. We evaluated rotarod performance, open-field behavior, and motor activity across the diurnal cycle in KI mice during early to mid-adulthood. Although we did not observe any effects of age, relative to wild-type (WT) mice, KI mice showed significant deficits in both open-field climbing behavior and home-cage running wheel activity during the light phase of the diurnal cycle. An interesting sex difference also emerged. KI females spent more time in the open-field grooming and more time running during the diurnal dark phase than KI males and WT mice of both sexes. In striatum, the primary site of HD pathology, we measured behavior-related changes in extracellular ascorbate (AA), which is abnormally low in the R6/2 line, consistent with a loss of antioxidant protection in HD. KI males exhibited a 20-40% decrease in striatal AA from anesthesia baseline to behavioral activation that was not observed in other groups. Collectively, our results indicate behavioral deficits in KI mice that may be specific to the diurnal cycle. Furthermore, sex differences observed in behavior and striatal AA release suggest sex-dependent variation in the phenotype and neuropathology of HD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17239451      PMCID: PMC1868463          DOI: 10.1016/j.bbr.2006.12.004

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  34 in total

1.  Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene.

Authors:  George V Rebec; Scott J Barton; Michelle D Ennis
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

2.  Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment.

Authors:  G V Rebec; S K Conroy; S J Barton
Journal:  Neuroscience       Date:  2005-10-28       Impact factor: 3.590

3.  Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration.

Authors:  K E Larsen; G G Behr; N Romero; S Przedborski; P Brundin; D Sulzer
Journal:  Hum Mol Genet       Date:  2001-06-01       Impact factor: 6.150

4.  NMDA receptor function in mouse models of Huntington disease.

Authors:  C Cepeda; M A Ariano; C R Calvert; J Flores-Hernández; S H Chandler; B R Leavitt; M R Hayden; M S Levine
Journal:  J Neurosci Res       Date:  2001-11-15       Impact factor: 4.164

5.  Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington's disease gene.

Authors:  I V Kovtun; T M Therneau; C T McMurray
Journal:  Hum Mol Genet       Date:  2000-11-01       Impact factor: 6.150

6.  CAG repeat lengths in X- and Y-bearing sperm indicate that gender bias during transmission of Huntington's disease gene is determined in the embryo.

Authors:  Irina V Kovtun; Glenn Welch; H David Guthrie; Kari L Hafner; Cynthia T McMurray
Journal:  J Biol Chem       Date:  2003-12-19       Impact factor: 5.157

7.  Inbred strain variation in lung function.

Authors:  Claudia Reinhard; Gunter Eder; Helmut Fuchs; Axel Ziesenis; Joachim Heyder; Holger Schulz
Journal:  Mamm Genome       Date:  2002-08       Impact factor: 2.957

8.  Mutant huntingtin enhances excitotoxic cell death.

Authors:  M M Zeron; N Chen; A Moshaver; A T Lee; C L Wellington; M R Hayden; L A Raymond
Journal:  Mol Cell Neurosci       Date:  2001-01       Impact factor: 4.314

9.  Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Liliana B Menalled; Jessica D Sison; Ioannis Dragatsis; Scott Zeitlin; Marie-Françoise Chesselet
Journal:  J Comp Neurol       Date:  2003-10-06       Impact factor: 3.215

10.  Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.

Authors:  George V Rebec; Scott J Barton; Ann M Marseilles; Kristin Collins
Journal:  Neuroreport       Date:  2003-07-01       Impact factor: 1.837

View more
  43 in total

1.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

2.  Substance abuse may be a risk factor for earlier onset of Huntington disease.

Authors:  Joanne A Byars; Leigh J Beglinger; David J Moser; Pedro Gonzalez-Alegre; Peg Nopoulos
Journal:  J Neurol       Date:  2012-01-25       Impact factor: 4.849

3.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

Review 4.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

5.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

6.  The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Authors:  A Reiner; D C Lafferty; H B Wang; N Del Mar; Y P Deng
Journal:  Neurobiol Dis       Date:  2012-03-27       Impact factor: 5.996

7.  Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease.

Authors:  Benjamin R Miller; Adam G Walker; Anand S Shah; Scott J Barton; George V Rebec
Journal:  J Neurophysiol       Date:  2008-07-30       Impact factor: 2.714

8.  Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease.

Authors:  Nigel I Wood; Valentina Carta; Stefan Milde; Elizabeth A Skillings; Catherine J McAllister; Y L Mabel Ang; Alasdair Duguid; Nadeev Wijesuriya; Samira Mohd Afzal; Joe X Fernandes; T W Leong; A Jennifer Morton; Jennifer Morton
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

9.  Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.

Authors:  B R Miller; J L Dorner; M Shou; Y Sari; S J Barton; D R Sengelaub; R T Kennedy; G V Rebec
Journal:  Neuroscience       Date:  2008-02-15       Impact factor: 3.590

10.  Altered information processing in the prefrontal cortex of Huntington's disease mouse models.

Authors:  Adam G Walker; Benjamin R Miller; Jenna N Fritsch; Scott J Barton; George V Rebec
Journal:  J Neurosci       Date:  2008-09-03       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.